Endocrine Abstracts

Glucocorticoid receptor (GR) gene polymorphisms have been associated with interindividual variations in glucocorticoid sensitivity in healthy individuals.Aim: Aim of this study was to investigate whether there was an association with sensitivity to glucocorticoids and bone mineral density in HPA axis disorders.Methods: We analyzed 3 polymorphisms of the GR gene (Bcl1, N363S, ER22/23EK) in 185 subjects: 52 patients with Cushing&#146...

Cushing’s disease (CD) occur more frequently in females than in males, but in men this disease seems appear at a younger age and with more severe symptoms and clinical course. Aim of this study was to compare clinical features and biochemical indices of hypercortisolism in male and female patients with CD.Methods: Forty-five patients (35 females and 10 males) with confirmed CD were analyzed. All patients underwent a complete biochemical and endocrin...

Introduction and aim: A prompt diagnosis of Cushing’s Syndrome (CS) in high-risk populations is mandatory: 1-mg dexamethasone suppression test (1-mg DST); late night salivary cortisol (LNSC) and urinary free cortisol (UFC) are recommend, despite thresholds calculated in retrospective studies. Our aim was to study the diagnostic accuracy of LNSC measured with chemiluminescence assay in a prospective study, confirming discrepancies with mass spectrometry (MS).<p class="...

Background: ACTH-secreting pituitary adenomas represent two-thirds of Cushing’s syndrome (CS), the so-called Cushing’s disease (CD). These tumors are sometimes >10 mm in maximal diameter (macro-CD), but the majority of them are <10 mm (micro-CD). The aim of this study was to compare baseline characteristics of patients with micro-CD and macro-CD.Materials and methods: Clinical, hormonal and radiological data of 226 patients with CD were...

Patients with adrenal insufficiency show higher mortality than in the general population, mainly due to non-physiological daily glucocorticoid overexposure and to inadequate cortisol exposure during stress-related events and illness. The aim of the current study is to compare the impact of 10 years of conventional glucocorticoid (GC) replacement treatment and dual-release hydrocortisone (DR-HC), on anthropometric, metabolic, cardiovascular and bone outcomes in treatment-na&#23...

Objective: In Cushing’s Syndrome, chronic glucocorticoid excess and their disrupted circadian rhythm lead to insulin-resistance, diabetes mellitus, dyslipidemia and cardiovascular comorbidities. As undifferentiated, self-renewing progenitors of adipocytes, mesenchymal stem cells may display the detrimental effects of glucocorticoid excess, thus revealing a promising model to study molecular mechanisms underlying metabolic complications of Cushing’s Syndrome.<p cl...

Background: Dysnatremia is common in hospitalized patients, often worsening the prognosis in pneumopathies and critical illnesses, such as COVID-19. Here, hyponatremia is an indicator of pulmonary involvement, while hypernatremia is associated with worse assistance outcomes, particularly when resulting from an overcorrected hyponatremia. Longer hospitalizations, readmissions after discharge and higher short- and long-term mortality rates have been observed in acute patients ex...

Introduction: Pasireotide is the first pituitary-directed drug approved for Cushing’s disease (CD). We report our 10-years experience with pasireotide in CD reviewing and analysing data about all the patients treated with pasireotide at our referral centre both in randomised trials and in clinical practice.Patients and methods: Twenty active CD patients were treated. Fourteen patients were treated with pasireotide in randomised trials and six patien...

Introduction: New onset diabetes after transplantation (NODAT) is a recognized metabolic complication of kidney transplantation: its rates at 12 months after transplantation is between 20 and 50% for kidney recipients and it is associated with increased risks of graft rejection, infection, cardiovascular disease and death. Transplant-specific risk factors for NODAT,such as corticosteroids and calcineurin inhibitors, play a dominant role in its pathogenesis. Furthermore polymor...

IntroductionThe oral 11β-hydroxylase inhibitor, osilodrostat, normalized mean urinary free cortisol (mUFC) in 79% (15/19) of patients with Cushing’s disease at the end of the 22-week core LINC 2 study. Long-term efficacy and safety data following an optional extension phase are reported here.MethodsPatients with clinical benefit at week 22 could continue receiving osilodrostat during the extension; ...